MX2012008658A - Inhibidores del virus de la hepatitis c. - Google Patents
Inhibidores del virus de la hepatitis c.Info
- Publication number
- MX2012008658A MX2012008658A MX2012008658A MX2012008658A MX2012008658A MX 2012008658 A MX2012008658 A MX 2012008658A MX 2012008658 A MX2012008658 A MX 2012008658A MX 2012008658 A MX2012008658 A MX 2012008658A MX 2012008658 A MX2012008658 A MX 2012008658A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- hepatitis
- compounds
- virus
- hcv infection
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención describe compuestos de la Fórmula (I) y sales, ésteres o profármacos farmacéuticamente aceptables de los mismos: Q-G-A-L-B-W (I), que inhiben virus que contienen ARN, particularmente el virus de la hepatitis C (VHC). En consecuencia, los compuestos de la presente invención interfieren con el ciclo de vida del virus de la hepatitis C y también son útiles como agentes antivirales. La presente invención además se refiere a composiciones farmacéuticas que comprenden los compuestos anteriormente mencionados, para la administración a un sujeto que sufra de una infección por VHC. La invención también se refiere a métodos para el tratamiento de una infección por VHC en un sujeto, mediante la administración de una composición farmacéutica que comprende los compuestos de la presente invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29791810P | 2010-01-25 | 2010-01-25 | |
US31430410P | 2010-03-16 | 2010-03-16 | |
PCT/US2011/022401 WO2011091417A1 (en) | 2010-01-25 | 2011-01-25 | Hepatitis c virus inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012008658A true MX2012008658A (es) | 2012-12-05 |
Family
ID=44307283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008658A MX2012008658A (es) | 2010-01-25 | 2011-01-25 | Inhibidores del virus de la hepatitis c. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8785487B2 (es) |
EP (1) | EP2528436A4 (es) |
JP (1) | JP2013518060A (es) |
KR (1) | KR20120107529A (es) |
CN (1) | CN102843909A (es) |
AU (1) | AU2011207492A1 (es) |
BR (1) | BR112012018529A2 (es) |
CA (1) | CA2787309A1 (es) |
CL (1) | CL2012002057A1 (es) |
CO (1) | CO6571891A2 (es) |
CR (1) | CR20120397A (es) |
CU (1) | CU20120110A7 (es) |
EA (1) | EA201201031A1 (es) |
EC (1) | ECSP12012067A (es) |
GT (1) | GT201200230A (es) |
IL (1) | IL221033A0 (es) |
MA (1) | MA34013B1 (es) |
MX (1) | MX2012008658A (es) |
PE (1) | PE20130244A1 (es) |
SG (1) | SG188957A1 (es) |
TN (1) | TN2012000358A1 (es) |
WO (1) | WO2011091417A1 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132031B2 (en) | 2006-09-26 | 2015-09-15 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US20080077201A1 (en) | 2006-09-26 | 2008-03-27 | Juniper Medical, Inc. | Cooling devices with flexible sensors |
US8192474B2 (en) | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US20080287839A1 (en) | 2007-05-18 | 2008-11-20 | Juniper Medical, Inc. | Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator |
US8523927B2 (en) | 2007-07-13 | 2013-09-03 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
ES2693430T3 (es) | 2007-08-21 | 2018-12-11 | Zeltiq Aesthetics, Inc. | Monitorización del enfriamiento de células subcutáneas ricas en lípidos, como el enfriamiento de tejido adiposo |
US8603073B2 (en) | 2008-12-17 | 2013-12-10 | Zeltiq Aesthetics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2419404B1 (en) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
EP2769703B1 (en) | 2009-04-30 | 2022-04-06 | Zeltiq Aesthetics, Inc. | Device for removing heat from subcutaneous lipid-rich cells |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ591973A (en) * | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2011207506A1 (en) | 2010-01-25 | 2012-08-09 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2550267A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
US8676338B2 (en) | 2010-07-20 | 2014-03-18 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US10722395B2 (en) | 2011-01-25 | 2020-07-28 | Zeltiq Aesthetics, Inc. | Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
EP2709455A4 (en) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES |
JP2014534206A (ja) | 2011-10-17 | 2014-12-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤 |
BR112014005617A2 (pt) * | 2011-10-21 | 2017-06-13 | Abbvie Inc | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013163270A1 (en) * | 2012-04-25 | 2013-10-31 | Theravance, Inc. | Hepatitis c virus inhibitors |
WO2014055069A1 (en) * | 2012-10-02 | 2014-04-10 | Presidio Pharmaceuticals, Inc. | Solid forms comprising an inhibitor of hcv ns5a, compositions thereof, and uses therewith |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
EP3099260A2 (en) | 2014-01-31 | 2016-12-07 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing for other treatments |
CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
US10675176B1 (en) | 2014-03-19 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Treatment systems, devices, and methods for cooling targeted tissue |
USD777338S1 (en) | 2014-03-20 | 2017-01-24 | Zeltiq Aesthetics, Inc. | Cryotherapy applicator for cooling tissue |
US10952891B1 (en) | 2014-05-13 | 2021-03-23 | Zeltiq Aesthetics, Inc. | Treatment systems with adjustable gap applicators and methods for cooling tissue |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
CN108727417B (zh) * | 2015-02-05 | 2021-10-08 | 爱博新药研发(上海)有限公司 | 多环化合物钠盐及其多晶型、制备方法及应用 |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2892598T3 (es) | 2015-10-19 | 2022-02-04 | Zeltiq Aesthetics Inc | Métodos de tratamiento vascular para enfriar estructuras vasculares |
CN108472151B (zh) | 2016-01-07 | 2020-10-27 | 斯尔替克美学股份有限公司 | 在组织冷却期间施用器与皮肤之间的温度依赖性粘附 |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
WO2019210223A1 (en) | 2018-04-26 | 2019-10-31 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
US11446175B2 (en) | 2018-07-31 | 2022-09-20 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
CA3124783A1 (en) * | 2018-12-27 | 2020-07-02 | Taisho Pharmaceutical Co., Ltd. | Pyrazolo[1,5-a]pyrimidine macrocyclic compound |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US3976545A (en) * | 1973-03-12 | 1976-08-24 | Icn Pharmaceuticals, Inc. | 1,2,4-Triazol E-3-carboxamides as antiviral agents |
US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
PT727419E (pt) | 1992-12-29 | 2002-08-30 | Abbott Lab | Compostos intermediarios para a preparacao de inibidores da protease retroviral |
US5935982A (en) | 1997-02-28 | 1999-08-10 | The University Of North Carolina At Chapel Hill | Methods of treating retroviral infection and compounds useful therefor |
AU2001278480A1 (en) | 2000-07-24 | 2002-02-05 | Bayer Crop Science Ag | Biphenyl carboxamides |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
FR2834725B1 (fr) * | 2002-01-15 | 2004-06-11 | Rieter Perfojet | Machine de production d'un produit textile a motifs et produit non tisse ainsi obtenu |
GB0229518D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
TW201018661A (en) | 2003-03-14 | 2010-05-16 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
US20050037214A1 (en) * | 2003-07-17 | 2005-02-17 | Fish Robert B. | Nylon composite articles of manufacture and processes for their preparation |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
CN102020697B (zh) | 2003-10-14 | 2014-10-29 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
US20060003942A1 (en) | 2003-10-27 | 2006-01-05 | Roger Tung | Combinations for HCV treatment |
NZ548074A (en) | 2003-12-22 | 2010-08-27 | Gerhard Puerstinger | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7894996B2 (en) | 2005-02-28 | 2011-02-22 | The Rockefeller University | Structure of the hepatitis C NS5A protein |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US7595340B2 (en) * | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
KR101294467B1 (ko) | 2005-07-25 | 2013-09-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 거대고리형 억제제 |
US7368024B2 (en) * | 2005-09-01 | 2008-05-06 | The Goodyear Tire & Rubber Company | Balanced tire assembly and method |
AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
SE529570C2 (sv) * | 2006-01-31 | 2007-09-18 | Cargine Engineering Ab | Tvåtakts förbränningsmotor |
GB0608899D0 (en) | 2006-05-05 | 2006-06-14 | Leuven K U Res & Dev | Novel viral replication inhibitors |
CN102724732B (zh) * | 2006-07-04 | 2015-04-15 | 株式会社日立制作所 | 自组织网络的构筑方法 |
US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
US20080019303A1 (en) * | 2006-07-21 | 2008-01-24 | Troicom, Inc. | Adaptive resource allocation for orthogonal frequency division multiple access |
WO2008019289A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20090317360A1 (en) | 2007-06-12 | 2009-12-24 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US20090047247A1 (en) | 2007-08-13 | 2009-02-19 | Yao-Ling Qiu | Pyrrolidine Derivatives |
US20090060874A1 (en) | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
KR20100123717A (ko) | 2008-02-12 | 2010-11-24 | 브리스톨-마이어스 스큅 컴퍼니 | C형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 |
JP5314053B2 (ja) | 2008-02-12 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
ES2391600T3 (es) | 2008-02-13 | 2012-11-28 | Bristol-Myers Squibb Company | Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY31685A (es) | 2008-03-04 | 2009-11-10 | Smithkline Beecham Corp | Compuestos antivirales, composiciones y metodos para usarlos |
WO2010014744A1 (en) | 2008-07-29 | 2010-02-04 | The Scripps Research Institute | Inhibitors of hepatitis c virus infection |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2373172B1 (en) | 2008-12-03 | 2013-07-17 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
KR20110098779A (ko) | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8420686B2 (en) | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
CA2753313A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
US8426458B2 (en) | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
CN102427729B (zh) | 2009-03-27 | 2014-09-03 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2419404B1 (en) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
JP2012524761A (ja) | 2009-04-24 | 2012-10-18 | テイボテク・フアーマシユーチカルズ | ジアリールエーテル類 |
US8414436B2 (en) * | 2009-04-30 | 2013-04-09 | GM Global Technology Operations LLC | Hybrid powertrain and method of operating same |
US9139569B2 (en) | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
TWI689305B (zh) | 2009-05-13 | 2020-04-01 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物 |
US8545161B2 (en) * | 2009-05-29 | 2013-10-01 | Peter WANEK-PUSSET | Unloading vehicle and combination of an unloading vehicle with a container |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
JP2012528194A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物 |
NZ591973A (en) | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
AU2010280711A1 (en) | 2009-08-07 | 2012-02-09 | Janssen Sciences Ireland Uc | Phenyl ethynyl derivatives as hepatitis C virus inhibitors |
EP2462135A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
US20120172368A1 (en) | 2009-09-03 | 2012-07-05 | Koen Vandyck | Bis-Benzimidazole Derivatives |
EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
MX2012010252A (es) * | 2010-03-04 | 2013-02-01 | Enanta Pharm Inc | Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv). |
EP2555622A4 (en) * | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
-
2011
- 2011-01-25 BR BR112012018529A patent/BR112012018529A2/pt not_active IP Right Cessation
- 2011-01-25 WO PCT/US2011/022401 patent/WO2011091417A1/en active Application Filing
- 2011-01-25 AU AU2011207492A patent/AU2011207492A1/en not_active Abandoned
- 2011-01-25 KR KR1020127022155A patent/KR20120107529A/ko not_active Application Discontinuation
- 2011-01-25 SG SG2013016357A patent/SG188957A1/en unknown
- 2011-01-25 MA MA35161A patent/MA34013B1/fr unknown
- 2011-01-25 MX MX2012008658A patent/MX2012008658A/es not_active Application Discontinuation
- 2011-01-25 CN CN2011800153764A patent/CN102843909A/zh active Pending
- 2011-01-25 US US13/013,212 patent/US8785487B2/en active Active
- 2011-01-25 PE PE2012001072A patent/PE20130244A1/es not_active Application Discontinuation
- 2011-01-25 CA CA2787309A patent/CA2787309A1/en not_active Abandoned
- 2011-01-25 JP JP2012550208A patent/JP2013518060A/ja not_active Withdrawn
- 2011-01-25 EA EA201201031A patent/EA201201031A1/ru unknown
- 2011-01-25 EP EP11735350.8A patent/EP2528436A4/en not_active Withdrawn
-
2012
- 2012-07-16 TN TNP2012000358A patent/TN2012000358A1/en unknown
- 2012-07-19 IL IL221033A patent/IL221033A0/en unknown
- 2012-07-24 CL CL2012002057A patent/CL2012002057A1/es unknown
- 2012-07-24 CU CU2012000110A patent/CU20120110A7/es unknown
- 2012-07-25 EC ECSP12012067 patent/ECSP12012067A/es unknown
- 2012-07-25 CO CO12125014A patent/CO6571891A2/es not_active Application Discontinuation
- 2012-07-25 GT GT201200230A patent/GT201200230A/es unknown
- 2012-07-26 CR CR20120397A patent/CR20120397A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011207492A1 (en) | 2012-08-16 |
CA2787309A1 (en) | 2011-07-28 |
JP2013518060A (ja) | 2013-05-20 |
EP2528436A1 (en) | 2012-12-05 |
GT201200230A (es) | 2015-06-02 |
CL2012002057A1 (es) | 2013-05-10 |
IL221033A0 (en) | 2012-09-24 |
BR112012018529A2 (pt) | 2016-08-09 |
CO6571891A2 (es) | 2012-11-30 |
MA34013B1 (fr) | 2013-02-01 |
CU20120110A7 (es) | 2012-12-17 |
CR20120397A (es) | 2013-05-15 |
WO2011091417A1 (en) | 2011-07-28 |
EA201201031A1 (ru) | 2013-02-28 |
SG188957A1 (en) | 2013-05-31 |
KR20120107529A (ko) | 2012-10-02 |
US20110189129A1 (en) | 2011-08-04 |
EP2528436A4 (en) | 2013-07-10 |
TN2012000358A1 (en) | 2014-01-30 |
ECSP12012067A (es) | 2012-12-28 |
CN102843909A (zh) | 2012-12-26 |
PE20130244A1 (es) | 2013-03-10 |
US8785487B2 (en) | 2014-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
MY160130A (en) | Hepatitis c virus inhibitors | |
MX2019013037A (es) | Prolina macrociclica derivada de inhibidores de serina proteasa de vhc. | |
PH12018550148A1 (en) | Hepatitis b antiviral agents | |
WO2013059278A3 (en) | Hepatitis c virus inhibitors | |
MX2011012155A (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c. | |
MX2010010276A (es) | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. | |
MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
MX2010006209A (es) | Derivados de quinoxalinilo. | |
WO2011049908A3 (en) | Bismacrokyclic compounds as hepatitis c virus inhibitors | |
PH12020550065A1 (en) | Hepatitis b antiviral agents | |
WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
MX2010005261A (es) | Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo. | |
MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
NZ600817A (en) | Inhibitors of flaviviridae viruses | |
MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |